Global Eukaryotic Translation Initiation Factor 4E (eIF-4E) Therapeutics Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Eukaryotic Translation Initiation Factor 4E (eIF-4E), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eukaryotic Translation Initiation Factor 4E (eIF-4E) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Eukaryotic Translation Initiation Factor 4E (eIF-4E) Overview
  3. Therapeutics Development
  4. Pipeline Products for Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Overview
  5. Pipeline Products for Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Comparative Analysis
  6. Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Therapeutics under Development by Companies
  7. Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Therapeutics under Investigation by Universities/Institutes
  8. Eukaryotic Translation Initiation Factor 4E (eIF-4E) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Development by Companies
  13. Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Investigation by Universities/Institutes
  14. Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Companies Involved in Therapeutics Development
  • eFFECTOR Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Onconova Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/w8t5ck/eukaryotic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs